Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Current Leases (2019 - 2025)

Protalix BioTherapeutics (PLX) has 7 years of Current Leases data on record, last reported at $1.4 million in Q3 2025.

  • For Q3 2025, Current Leases fell 7.36% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, down 7.36%, while the annual FY2024 figure was $1.5 million, 6.46% up from the prior year.
  • Current Leases reached $1.4 million in Q3 2025 per PLX's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $1.5 million in Q3 2024 and bottomed at $1.0 million in Q3 2022.
  • Average Current Leases over 5 years is $1.3 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Current Leases: dropped 19.03% in 2022, then soared 31.3% in 2023.
  • A 5-year view of Current Leases shows it stood at $1.2 million in 2021, then dropped by 7.37% to $1.1 million in 2022, then grew by 26.03% to $1.4 million in 2023, then grew by 6.46% to $1.5 million in 2024, then fell by 6.87% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $1.4 million in Q3 2025, $1.5 million in Q2 2025, and $1.4 million in Q1 2025.